Globus strengthens position as UK's leading force in hand protection
Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.
From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.
Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.
Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
You may also like
                                                                            Regulatory
                                                
                            
                                
                            
                            
                NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
Read moreNew draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
                                
                        
                    Trending Articles
You may also like
                                                            Regulatory
                                                        
                                
                                                                            
                                                                    
                                
                    NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions
New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date